News
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
23 Apr 24
Biotech, Large Cap, News, Health Care, Movers, Trading Ideas, General
Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
19 Apr 24
News
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan For Patients With Congenital Thrombotic Thrombocytopenic Purpura
26 Mar 24
Biotech, News, General
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application For ICLUSIG In Adult Patients With Newly Diagnosed Ph+ ALL
19 Mar 24
Biotech, News, FDA, General
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
19 Mar 24
News
Takeda Announces Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079) For Primary Immune Thrombocytopenia
13 Mar 24
Biotech, Large Cap, News, Health Care, General
Takeda And Biological E. Limited Enter Strategic Partnership To Accelerate Access To Dengue Vaccine In Endemic Areas
27 Feb 24
News
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
12 Feb 24
Biotech, Equities, Large Cap, News, Health Care, FDA, Movers, Trading Ideas, General
FDA Approves Takeda's EOHILIA, The First And Only Oral Treatment In The U.S. For Eosinophilic Esophagitis
12 Feb 24
Biotech, News, FDA, General
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study
9 Feb 24
Biotech, Large Cap, News, Health Care, General
Takeda Says It Does Not Plan To Advance TAK-861 In Narcolepsy Type 2 At This Time; Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolepsy Type 1 Rapidly In H1 Of Its FY24
8 Feb 24
News
Takeda Says Primary And Key Secondary Endpoints Were Met In Narcolepsy Type 1 Phase 2b Trial;
8 Feb 24
News
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
1 Feb 24
Biotech, Earnings, Large Cap, News, Guidance, Health Care, Contracts, Management, Movers, Trading Ideas, General
Earnings Scheduled For February 1, 2024
1 Feb 24
Earnings
Takeda Names Milano Furuta As Chief Financial Officer, Effective April 1, 2024
1 Feb 24
News, Management
Takeda Reaffirms Fiscal 2023 Guidance, Revenue Of JPY3.98T, And Core EPS Of JPY447
1 Feb 24
News, Guidance
Takeda's GAMMAGARD LIQUID Approved By FDA For Adults with Chronic Inflammatory Demyelinating Polyneuropathy
29 Jan 24
Biotech, News, FDA, General
European Commission Approves Takeda's HYQVIA As Maintenance Therapy In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
29 Jan 24
News
Press releases
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
22 Apr 24
Press Releases
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
18 Apr 24
Press Releases
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
27 Mar 24
Small Cap, Press Releases
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
26 Mar 24
Press Releases
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
13 Mar 24
Press Releases
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
26 Feb 24
Press Releases
Championing Rare Voices on Rare Disease Day
26 Feb 24
Press Releases
Takeda Supports the Canadian IBD Research Consortium's $1 Million Pioneer Grant for Second Year
13 Feb 24
Press Releases
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
8 Feb 24
Press Releases
Takeda Announces Chief Financial Officer Succession
1 Feb 24
Press Releases
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
1 Feb 24
Press Releases
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
31 Jan 24
Contracts, Press Releases
Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
29 Jan 24
Press Releases